This month's top tech news stories
Nykode Therapeutics
Manufacturing partnership
Nykode Therapeutics, a clinical-stage biopharmaceutical company, has entered into a strategic manufacturing partnership with Richter-Helm to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “As a leading manufacturer of DNA vaccines, they will provide the long-term expertise and capacity needed to support our ambitious growth and pipeline development,” said Mette Husbyn, Nykode Therapeutics Chief Technology Officer.
Sheffield Teaching Hospitals
Cardiovascular diagnostics
An artificial intelligence (AI) tool that provides a quick and comprehensive analysis of the heart’s function could improve future cardiovascular care by aiding earlier diagnosis and giving more detailed information about the heart’s function. Developed by researchers at Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield, the tool detects chambers of the heart on MRI images – performing in seconds tasks that would involve lengthy manual analysis.
LGC Clinical Diagnostics
Diabetes Kit
LGC Clinical Diagnostics announced the addition of Cystatin C to Maine Standards Validate diabetes kit for the Roche cobas platforms for easy, fast, reliable documentation of linearity and calibration verification. The product – with the analytes Beta-Hydroxybutyrate, C-Peptide, Insulin, Fructosamine, and now Cystatin C – is formulated in human serum, using the CLSI EP06 “equal delta” sample preparation method, and provides five distinct concentrations. Validate diabetes test kits are frozen liquid and ready to use – dispense the solution from each dropper bottle, directly into five sample cups, and run in replicates to verify the assay’s reportable range.
Image credit | Shutterstock | Sheffield Teaching Hospitals NHS Foundation Trust
